Mene Pangalos is Executive Vice-President, Research & Development BioPharmaceuticals.
A member of the company’s Senior Executive team, Mene has overall responsibility for AstraZeneca’s research and early development activities spanning three continents and 2500 people.
Since joining AstraZeneca in 2010, Mene has been instrumental in transforming the company’s commitment to science. He has led the transformation of R&D productivity through the development and implementation of the “5R” framework; driven greater collaboration with academic, NGO and peer organisations; pioneered programmes to promote more open innovation and fostered a science driven culture that rewards truth-seeking behaviours.
As one of AstraZeneca’s leading scientists, Mene has published over 145 peer-reviewed articles in scientific journals and has served as editor of a number of books and journals. Mene is a Visiting Professor of Neuroscience at King’s College London and the holder of an Honorary degree of Doctor of Science from Glasgow University.
He is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He serves on the Medical Research Council (MRC) Council, co-chairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also a Board member of the British Pharmaceutical Group, Cambridge University’s Judge Business School and Dizal Pharma, a privately owned Chinese biotech.
Mene also oversees the creation of AstraZeneca’s new research centre and Global Headquarters in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.